Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

<ul>
<li>Sirnaomics is a biotech with a focus on siRNA technology for oncology and fibrosis diseases, and is looking to raise up to USD 150m via a Hong Kong listing.</li>
<li>We look at the company's core products, including STP705 and STP707. Having looked at the company's products, we aren't convinced that they can be blockbuster drugs.</li>
<li>We think the company's product pipeline is too light. The company management lacks track record in siRNA development and investors are mostly domestic individuals and funds.</li>
</ul>


Sirnaomics is a biotech with a focus on siRNA technology for oncology and fibrosis diseases, and is looking to raise up to USD 150m via a Hong Kong listing.
We look at the company's core products, including STP705 and STP707. Having looked at the company's products, we aren't convinced that they can be blockbuster drugs.
We think the company's product pipeline is too light. The company management lacks track record in siRNA development and investors are mostly domestic individuals and funds.


Sirnaomics Pre-IPO: Not a Convincing siRNA Pipeline

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<p>In recent years, with the successful development and large-scale use of mRNA COVID-19 vaccine worldwide, RNA-based therapeutics have caught the attention of the public. Meanwhile, with the advancement of target discovery technology and the maturation of chemical modification and delivery technology, RNA-based therapeutics are expected to become a major treatment option in the future. On July 15, 2021, <a href="https://www.smartkarma.com/entities/sirnaomics-inc" target="_blank" data-smartkarma-citation="entities:33804:1" rel="noopener">Sirnaomics (1400833D US)</a>, the first and only clinical-stage RNA therapeutics biopharmaceutical company, formally submitted its prospectus to the HKEX for listing on the main board. This insight mainly analyzed the industry characteristics, the delivery platforms, the pipeline and the concerns of the Company.</p>

In recent years, with the successful development and large-scale use of mRNA COVID-19 vaccine worldwide, RNA-based therapeutics have caught the attention of the public. Meanwhile, with the advancement of target discovery technology and the maturation of chemical modification and delivery technology, RNA-based therapeutics are expected to become a major treatment option in the future. On July 15, 2021, Sirnaomics (1400833D US), the first and only clinical-stage RNA therapeutics biopharmaceutical company, formally submitted its prospectus to the HKEX for listing on the main board. This insight mainly analyzed the industry characteristics, the delivery platforms, the pipeline and the concerns of the Company.

Pre-IPO Sirnaomics Ltd. - Cautious Optimism Is Still Recommended

Hong Kong

Sirnaomics is an RNA therapeutics biopharmaceutical company that discovers and develops innovative drugs for indications with unmet medical needs. The company leverages its proprietary polypeptide nanoparticle (PNP) and GalNAc RNAi platforms (GalAhead™) to build a pipeline of drug candidates, including STP705 and STP707 for oncology and fibrosis, and STP122G for anticoagulant therapies. Headquartered in Gaithersburg, MD, United States, the company was founded in 2007.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sirnaomics (2257 HK)

Sirnaomics Pre-IPO: Not a Convincing siRNA Pipeline

Sirnaomics, a US and China based biotech company focusing on the siRNA, is looking for a listing in Hong Kong. We look at the siRNA technology and...

Ke Yan, CFA, FRM

Pre-IPO Sirnaomics Ltd. - Cautious Optimism Is Still Recommended

This article mainly analyzed Sirnaomics in terms of the industry characteristics, the delivery platforms, the pipeline and the concerns of the...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)